Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples